NASDAQ$TNGX
Tango Therapeutics Inc · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Tango Therapeutics reported Q1 2026 collaboration revenue of $0 with a net loss of $45.5M and diluted loss per share of $0.32.
For the quarter ended March 31, 2026, Tango recognized no collaboration revenue versus $12.5 million in Q1 2025 as prior GSK-related revenue rolled off. Net loss was $45.5 million compared with $28.0 million, with diluted loss per share of $0.32 versus $0.21. R&D expense rose to $42.8 million on synthetic-lethality program advancement.
- Collaboration revenue fell to $0 from $12.5M year over year.
- Net loss widened to $45.5M; diluted EPS was a loss of $0.32.
- R&D expense of $42.8M reflects active oncology pipeline work.
- Cash and investments support continued clinical trials per MD&A.
- Lead programs target MTAP-deleted and other synthetic-lethality tumors.
Headline financials
Revenue & EPS history
Tango Therapeutics · Revenue · Quarterly
$0
Forward guidance
Tango does not issue EPS or revenue guidance in the 10-Q and expects continued losses while advancing TNG462 and other targeted oncology candidates.
Tailwinds
- Strong cash balance supports multi-program clinical execution.
- Pipeline progress on synthetic-lethality targets continues.
Headwinds
- Absence of collaboration revenue increased net loss year over year.
- R&D spend growth pressures cash runway.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2026
+0.6%
Avg return
Earnings day
+6.7%
Avg return
5 days after
+25.8%
Avg return
30 days after
58%
11 / 19 earnings
Positive
+36.4%
Q4 2025
Best reaction
-45.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +8.6% | -12.1% | +31.7% | |
| Q4 2025 | +36.4% | +33.6% | +75.1% | |
| Q3 2025 | +0.2% | -1.7% | +23.6% | |
| Q1 2025 | +17.1% | +31.6% | +315.8% | |
| Q4 2024 | -6.5% | -21.0% | -36.9% | |
| Q3 2024 | -45.4% | -34.7% | -34.7% | |
| Q2 2024 | -1.8% | -5.7% | +20.9% | |
| Q1 2024 | -0.8% | -6.9% | -12.1% | |
| Q4 2023 | -9.7% | -14.4% | -17.4% | |
| Q3 2023 | +3.8% | -12.1% | +6.6% | |
| Q2 2023 | +1.2% | +120.9% | +113.5% | |
| Q1 2023 | +6.4% | +4.4% | -0.3% | |
| Q4 2022 | -9.4% | -5.3% | -21.6% | |
| Q3 2022 | -5.3% | +6.7% | -1.3% | |
| Q2 2022 | +22.4% | +32.8% | -8.1% | |
| Q1 2022 | -7.6% | +1.2% | -3.8% | |
| Q4 2021 | +0.3% | +6.8% | +1.3% | |
| Q3 2021 | +0.4% | +5.2% | -10.7% | |
| Q2 2021 | +1.1% | -2.2% | +49.4% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro